Quest Diagnostics Incorporated — Q1 2012 Form 10-Q
Business context and period: U.S.-based diagnostic testing, information and services provider; clinical testing generated more than 90% of continuing-operations revenue. Unaudited results cover the three months ended March 31, 2012, compared with Q1 2011. Dollar figures below are USD millions unless stated otherwise.
Financial performance
| Metric | Q1 2012 | Q1 2011 | Change / context |
|---|---|---|---|
| Net revenue | $1,936.5 | $1,821.6 | Up 6.3%; acquisitions contributed 3.2 percentage points of growth. |
| Operating income | $299.6 | $31.0 | Operating margin 15.5% vs. 1.7%; prior period included a $236 million Medi-Cal charge. |
| Income from continuing operations attributable to Quest | $158.8 | $(53.5) | Prior period loss reflected the Medi-Cal charge. |
| Net income attributable to Quest | $159.1 | $(53.9) | Includes discontinued operations of $0.3 million vs. a $0.4 million loss. |
| Diluted EPS | $0.99 | $(0.33) | 2012 included $0.08 per share of restructuring/integration and CEO-succession costs; 2011 included $1.19 per share for the Medi-Cal charge. |
| Operating cash flow | $161.3 | $160.6 | Essentially unchanged. |
Cost of services was 57.7% of revenue, down from 60.2%; SG&A was 25.8%, up from 24.6%. Net interest expense increased to $42.3 million from $37.9 million, primarily due to higher average debt. Dividends declared were $0.17 per share, up from $0.10.
Liquidity, debt and capital allocation
- At March 31, cash was $145.4 million, versus $164.9 million at year-end 2011. Current assets of $1,518.6 million were slightly below current liabilities of $1,525.4 million.
- Balance-sheet debt was approximately $3,919.6 million, combining $554.4 million of short-term/current debt and $3,365.3 million of long-term debt. Estimated fair value was $4.3 billion. Debt principal in the contractual-obligations table was $3,845 million.
- Investing cash outflow was $83.2 million, including the $50.6 million S.E.D. acquisition and $30.0 million of capital expenditures. Financing cash outflow was $97.5 million; debt repayments exceeded borrowings by $102.3 million. The filing estimates 2012 capital expenditures of $200–$225 million.
- Available borrowing capacity was approximately $1.0 billion: $260 million under the secured receivables facility and $750 million under the revolving facility. No revolving-facility borrowings were outstanding at quarter-end. The company reported compliance with its debt covenants.
- Q1 share repurchases totaled $50 million (847,000 shares); approximately $1.0 billion remained authorized. Cash dividends paid were $26.9 million.
Material changes and management commentary
- Revenue growth reflected acquisitions of Athena, Celera and S.E.D. Clinical testing revenue rose 6.4%; requisition volume rose 3.4%, but management estimated underlying volume growth at about 1% after favorable weather and acquisition effects. Revenue per requisition rose 2.9%, partly reflecting greater gene-based and esoteric testing.
- Management cited cost-reduction actions and acquisition mix as contributors to lower cost of services as a share of revenue. Compensation and benefit increases, acquired operations, restructuring/integration spending and CEO-succession costs partly offset these gains.
- On February 28, 2012, the company committed to a multi-year plan targeting $500 million of cost reductions by year-end 2014. Estimated pretax implementation charges are $100–$175 million through 2014, of which $90–$155 million are expected to be cash expenditures. Management cautioned actual charges may differ materially.
- Management said cash on hand, operating cash flow and available credit should provide sufficient flexibility for working capital, capital spending, debt service, dividends, repurchases and growth opportunities. The filing gives no earnings or revenue guidance.
Risks, contingencies and unusual items
- Several legal matters remain pending, including billing/pricing investigations and litigation related to government healthcare programs. The company is cooperating with subpoenas and investigations. Legal reserves were below $5 million; management said potential losses on the described matters could not be estimated and are not considered probable, while acknowledging outcomes could affect results or cash flows materially in the period determined or paid.
- Reserves for general and professional liability claims were approximately $165 million, compared with $127 million at December 31, 2011. The company is self-insured for a significant portion of these claims.
- Unrecognized tax-benefit liabilities were approximately $211 million; up to approximately $17 million could decrease within the next twelve months, but timing for the remainder could not be reliably estimated.
- Variable-rate debt exposes the company to interest-rate changes; derivatives are used for risk management, not speculation. Management described foreign-exchange and commodity-price exposures as not material.
- The Q1 2011 comparison is materially affected by the $236 million Medi-Cal settlement charge and $18.5 million estimated adverse operating-income impact from severe weather. Q1 2012 included $13.1 million of restructuring/integration costs and $7.1 million related to CEO succession.
Important facts for investors to verify
- Whether the targeted $500 million of savings by 2014 is achieved, and the timing and cash impact of the estimated $100–$175 million in related charges.
- Underlying clinical-testing volume trends, excluding acquisition and weather effects, and the sustainability of revenue-per-requisition growth.
- Debt principal and near-term maturities, refinancing needs, borrowing capacity and covenant compliance; note the filing presents both balance-sheet carrying debt and contractual principal figures.
- Developments in government investigations, billing-related claims and professional-liability exposure, including any changes in reserves or estimable losses.
- Whether operating cash flow remains sufficient to support capital spending, debt service, dividends and repurchases amid reimbursement and labor-cost pressures.